To investigate whether FGFR4 and EZH2 inhibitors could synergistically repress tumor growth in vivo, we first administered Roblitinib and CPI-169 alone or in combination in the zebrafish HCC primary tumors. Here, EZH2 is linked to hepatocellular carcinoma.